Literature DB >> 24461432

Functional and computed tomographic evolution and survival of restrictive allograft syndrome after lung transplantation.

Stijn E Verleden1, Pim A de Jong2, David Ruttens3, Elly Vandermeulen3, Dirk E van Raemdonck3, Johny Verschakelen4, Bart M Vanaudenaerde3, Geert M Verleden3, Robin Vos3.   

Abstract

BACKGROUND: Restrictive allograft syndrome (RAS) has recently been defined as a novel phenotype of chronic lung allograft dysfunction (CLAD) after lung transplantation. The goal was to describe computed tomographic (CT) changes of RAS patients and to correlate this with spirometry and survival.
METHODS: All 24 established RAS patients at our center were retrospectively included. CT scans from pre-CLAD, CLAD, post-CLAD and late-CLAD subjects were systematically evaluated by a blinded observer using a semi-quantitative scoring system. Changes in CT patterns were correlated with spirometry and survival.
RESULTS: The most prominent CT features at diagnosis of CLAD as compared with pre-CLAD were appearance of central (p = 0.020) and peripheral ground glass opacities (p = 0.052), as well as septal and non-septal lines (p = 0.020). Survival after diagnosis of CLAD was only associated with the absolute value of forced vital capacity (FVC) at diagnosis (R = 0.46 and p = 0.021), and not with any CT alterations. Evolution of CT abnormalities after diagnosis of CLAD included significant increases in (traction) bronchiectasis (p < 0.0001), central (p = 0.051) and peripheral (p = 0.0002) consolidation, architectural deformation (p = 0.0002), volume loss (p = 0.0004) and hilus retraction (p = 0.0036). The absolute FVC decrease post-CLAD diagnosis correlated with CT alterations.
CONCLUSIONS: In the early stages of RAS, central and peripheral ground glass opacities are the most prominent feature on CT, whereas, in later stages, bronchiectasis, traction, central and peripheral consolidation, architectural deformation, volume loss and hilus retraction are more pronounced. CT changes, however, could not predict survival, whereas FVC at diagnosis of CLAD seems to be the best predictor of survival.
Copyright © 2014 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic lung allograft dysfunction; computed tomography; lung transplantation; restrictive allograft syndrome; spirometry; survival

Mesh:

Year:  2013        PMID: 24461432     DOI: 10.1016/j.healun.2013.12.011

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  14 in total

1.  Restrictive allograft syndrome after lung transplantation: new radiological insights.

Authors:  Adriana Dubbeldam; Caroline Barthels; Johan Coolen; Johny A Verschakelen; Stijn E Verleden; Robin Vos; Geert M Verleden; Walter De Wever
Journal:  Eur Radiol       Date:  2016-11-22       Impact factor: 5.315

2.  Spirometry States the Obvious: Recognizing Bronchiolitis Obliterans Syndrome Early after Hematopoietic Cell Transplantation.

Authors:  Elizabeth A Belloli; Vibha N Lama
Journal:  Ann Am Thorac Soc       Date:  2016-11

Review 3.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

4.  Longitudinal Forced Vital Capacity Monitoring as a Prognostic Adjunct after Lung Transplantation.

Authors:  Elizabeth A Belloli; Xin Wang; Susan Murray; Ginia Forrester; Adrian Weyhing; Jules Lin; Tammy Ojo; Vibha N Lama
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

5.  Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Megan L Neely; C A Finlen Copeland; Courtney W Frankel; John M Reynolds; Scott M Palmer
Journal:  J Heart Lung Transplant       Date:  2018-10-31       Impact factor: 10.247

6.  Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.

Authors:  Ramsey R Hachem; Malek Kamoun; Marie M Budev; Medhat Askar; Vivek N Ahya; James C Lee; Deborah J Levine; Marilyn S Pollack; Gundeep S Dhillon; David Weill; Kenneth B Schechtman; Lorriana E Leard; Jeffrey A Golden; LeeAnn Baxter-Lowe; Thalachallour Mohanakumar; Dolly B Tyan; Roger D Yusen
Journal:  Am J Transplant       Date:  2018-05-15       Impact factor: 8.086

Review 7.  Comprehensive Care of the Lung Transplant Patient.

Authors:  Ayodeji Adegunsoye; Mary E Strek; Edward Garrity; Robert Guzy; Remzi Bag
Journal:  Chest       Date:  2016-10-08       Impact factor: 9.410

8.  Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients.

Authors:  Francesca Mariani; Beatrice Gatti; Alberto Rocca; Francesca Bonifazi; Alberto Cavazza; Stefano Fanti; Sara Tomassetti; Sara Piciucchi; Venerino Poletti; Maurizio Zompatori
Journal:  Diagn Interv Radiol       Date:  2016 Sep-Oct       Impact factor: 2.630

9.  Parametric Response Mapping of Bronchiolitis Obliterans Syndrome Progression After Lung Transplantation.

Authors:  S E Verleden; R Vos; E Vandermeulen; D Ruttens; H Bellon; T Heigl; D E Van Raemdonck; G M Verleden; V Lama; B D Ross; C J Galbán; B M Vanaudenaerde
Journal:  Am J Transplant       Date:  2016-07-29       Impact factor: 8.086

Review 10.  Quantitative inspiratory-expiratory chest CT to evaluate pulmonary involvement in pediatric hematopoietic stem-cell transplantation patients.

Authors:  Francesca Pennati; Laura L Walkup; Anuj Chhabra; Christopher Towe; Kasiani Myers; Andrea Aliverti; Jason C Woods
Journal:  Pediatr Pulmonol       Date:  2020-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.